Allopurinol is the cornerstone of pharmacologic uratelowering therapy for recurrent gouty arthritis. Although this drug is inexpensive and efficacious, it may cause rare, but lifethreatening, cutaneous drug eruptions: the allopurinol hypersensitivity syndrome. 1 Mortality rates for individuals experiencing allopurinol hypersensitivity can exceed 30% and long-term morbidity is common.
both allopurinol prescribing and hypersensitivity reactions are on the rise. Their findings highlight the value of judicious, guideline-based hyperuricemia management throughout the world.
The authors used a retrospective cohort design to investigate the incidence and predictors of allopurinol hypersensitivity among almost every Taiwanese adult during a 6-year period. Using insurance claims, they found that the incidence of allopurinol prescribing and hypersensitivity increased over time, with an overall allopurinol hypersensitivity incidence of 0.4% among new users, 8.3% of whom died from the drug reaction. Hypersensitivity reactions were more likely among new users with chronic kidney disease or cardiovascular disease who received allopurinol for asymptomatic hyperuricemia as opposed to symptomatic gout; these patients represented 49.5% of new user prescriptions by the end of the study period. 
